What are the differences between insulin glargine 300 units/mL (U300) and insulin glargine 100 units/mL (U100)?

Insulin Glargine U300 vs U100: Key Differences

Insulin glargine U300 (Toujeo) requires approximately 10-20% higher doses than U100 (Lantus) to achieve equivalent glycemic control, but offers a longer duration of action (>24 hours) and significantly lower risk of nocturnal hypoglycemia. 1, 2

Concentration and Volume

• U300 is three times more concentrated than U100, delivering the same number of units in one-third the volume 1
• Both formulations contain identical insulin glargine molecules, but the concentration affects pharmacokinetics 3
• U300 is available only in prefilled pens to minimize dosing errors, while U100 comes in both vials and pens 1, 2

Pharmacokinetic Differences

Duration of Action:

• U300 has a longer duration of action (>24 hours) compared to U100 1, 4
• This extended duration provides more stable glucose-lowering throughout the day 4

Bioavailability:

• U300 has 50% lower bioavailability when given subcutaneously compared to U100 3
• The reduced bioavailability explains why higher doses are needed with U300
• When given intravenously, both formulations are equipotent, confirming the difference is absorption-related 3

Clinical Efficacy and Dosing

Dose Requirements:

• U300 requires 10-20% higher doses than U100 to achieve similar HbA1c reductions 1, 5, 6
• Real-world data shows doses 5-13% higher with U300 at 6-18 months 5
• When switching from U300 to U100, start with 80% of the U300 dose to reduce hypoglycemia risk 2

Glycemic Control:

• Both formulations achieve equivalent HbA1c reductions 4, 6, 7
• U300 provides a more stable glucose-lowering profile with less variability 4, 8

Hypoglycemia Risk

This is where U300 demonstrates clear superiority:

• Nocturnal hypoglycemia risk is significantly lower with U300 4, 9, 6

  • 23% relative risk reduction in nocturnal confirmed hypoglycemia (≤3.9 mmol/L) from week 9 to month 6 6
  • 35% lower risk of first severe hypoglycemia event in type 1 diabetes 9

• 24-hour hypoglycemia rates are also lower with U300 8, 6

• The Low Blood Glucose Index (LBGI) is significantly lower with U300, particularly at night 8

• In exercise scenarios, U300 at full dose showed 40% less time below range (<70 mg/dL) compared to degludec 10

Practical Clinical Considerations

Weight Gain:

• U300 is associated with less weight gain than U100 6

Treatment Satisfaction:

• Patients report greater flexibility and satisfaction with U300 4, 7
• Improved convenience scores in patient-reported outcomes 7

Dosing Flexibility:

• U300's longer duration allows for greater flexibility in administration timing 4

Critical Switching Guidance

When converting between formulations:

• U300 to U100: Start with 80% of U300 dose 2
• U100 to U300: Can start 1:1 but expect to titrate upward by 10-20% 1, 5
• Close glucose monitoring is mandatory during any insulin regimen change 2
• Increased frequency of blood glucose checks for several weeks after switching 2

Cost Considerations

The higher dose requirements of U300 translate to higher medication costs when priced per unit equivalently to U100 5. This real-world economic factor must be weighed against the clinical benefits of reduced hypoglycemia risk.

Bottom Line Algorithm

Choose U300 over U100 when:

• Nocturnal hypoglycemia is problematic
• Patient requires high basal insulin doses (concentrated formulation reduces injection volume)
• Flexible dosing timing is beneficial
• Patient engages in regular exercise (lower hypoglycemia risk)

Choose U100 over U300 when:

• Cost is a primary concern
• Patient requires vial formulation
• Lower total daily doses are needed
• Hypoglycemia is not a significant issue

Both formulations achieve equivalent glycemic control, but U300's superior hypoglycemia profile, particularly at night, makes it the preferred choice when hypoglycemia risk reduction is prioritized 9, 6.